Recurrence-Free Survival vs Overall Survival as a Primary Endpoint for Studies of Resected Colorectal Liver Metastasis
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
The Lancet Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Recurrence-free survival versus overall survival as a primary endpoint for studies of resected colorectal liver metastasis: a retrospective study and meta-analysis
Lancet Oncol 2022 Sep 01;[EPub Ahead of Print], BL Ecker, J Lee, LV Saadat, T Aparicio, FE Buisman, VP Balachandran, JA Drebin, K Hasegawa, WR Jarnagin, NE Kemeny, TP Kingham, B Groot Koerkamp, N Kokudo, Y Matsuyama, G Portier, LB Saltz, KC Soares, AC Wei, M Gonen, MI D'AngelicaFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.